E
EVOK
Evoke Pharma Inc
This stock has been delisted.
News
Press Releases
Financial Reports
Profile
Reuters·12/17/2025 15:51
Evoke Pharma Stockholders Receive $11 Per Share as QOL Medical Deal Closes
Dow Jones·12/17/2025 15:51
Press Release: Evoke Pharma and QOL Medical Announce Expiration of Tender Offer
Reuters·12/17/2025 15:50
EVOKE PHARMA AND QOL MEDICAL ANNOUNCE EXPIRATION OF TENDER OFFER
TipRanks·12/17/2025 14:27
Evoke Pharma Acquired by QOL Medical, Nasdaq Trading Ends
Dow Jones·11/27/2025 10:35
U.K. Gambling Stocks Benefit From Diversified Revenue -- Market Talk
TipRanks·11/18/2025 06:50
Evoke Pharma Reports Increased Sales Amid Ongoing Losses
TipRanks·11/16/2025 06:00
Evoke Pharma’s Merger Uncertainty: Potential Risks to Business Operations and Financial Health
Seeking Alpha·11/13/2025 12:27
Evoke Pharma GAAP EPS of -$0.45, revenue of $4.28M
Reuters·11/13/2025 12:14
Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025
Benzinga·11/13/2025 12:14
Evoke Pharma Q3 EPS $(0.45), Inline, Sales $4.284M Miss $4.326M Estimate
Dow Jones·11/13/2025 12:11
*Evoke Pharma: Transaction Expected to Close in 4Q >EVOK
Dow Jones·11/13/2025 12:10
*Evoke Pharma: QOL Medical to Acquire Evoke for $11 Per Shr >EVOK
Dow Jones·11/13/2025 12:09
*Evoke Pharma 3Q Sales $4.3M Vs. $2.7M >EVOK
Dow Jones·11/13/2025 12:08
*Evoke Pharma Agrees To Be Acquired by QOL Medical EVOK >
Dow Jones·11/13/2025 12:01
Press Release: Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.